immune response News
-
Study from Scripps using SpyTag/SpyCatcher for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development
A study from Scripps using SpyTag/SpyCatcher technology shows that the receptor-binding domain and stabilized SARS-CoV-2 spike displayed on ferritin nanoparticles as vaccine antigens, elicited potent immune responses. ...
-
Vicinivax Announces Last Patient Out In The Phase I Study With Immunotherapy Vvax001 ...
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
Prellis Biologics Announces Collaboration with Sanofi
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
-
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI ...
-
NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled ...
-
Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination
Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through Kephera’s CLIA-certified laboratory. Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is ...
-
Biosceptre Joins European Cooperation in Science & Technology COST Group BMBS 1406 – with focus on Ion Channels and Immune Response
Biosceptre announces today its membership of the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406. This project, established in 2014, created the Ion chan-Immune response network that brings together internationally recognised scientists and companies across 15 European countries with the common goal of understanding the function of ion channels in Bimmune ...
-
OncoImmunity starts a personalized cancer vaccine project with a Chinese biotech company
OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients. The collaboration will demonstrate the power of the ...
-
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune ...
-
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. (NASDAQ: HOOK, ...
-
PFCs, chemicals widespread in environment, linked to lowered immune response to childhood vaccinations
A new study finds that perfluorinated compounds (PFCs), widely used in manufactured products such as non-stick cookware, waterproof clothing, and fast-food packaging, were associated with lowered immune response to vaccinations in children. It is the first study to document how PFCs, which can be transferred to children prenatally (via the mother) and postnatally from exposure in the environment, ...
-
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
MeMed, a leader in host response technologies, today announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. ...
By MeMed
-
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific ...
-
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. ...
By Novavax
-
20th Annual Biotech in Europe Forum for global partnering & investments
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners. Please contact us for a personal meeting within the partnering system or outside it. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in ...
-
Bio International Convention Digital June 8-12, 2020
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the Switzerland Global Enteprise (https://www.s-ge.com/en/sbh) . We look forward meeting potential investors and licensing partners. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome ...
-
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive ...
-
NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets
GAITHERSBURG, Md., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Rutgers, The State University of New Jersey. The collaboration will focus on the ...
-
Covid-19 Vaccine Developed By Ub Startup Enters Human Trials
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. The vaccine candidate, called EuCorVac-19, was jointly developed by Buffalo biotech company POP Biotechnologies and South Korean biotech company EuBiologics. POP Biotechnologies was founded in 2015 by former UB students Kevin Carter and Jonathan Smyth and UB ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you